GlycoMimetics (GLYC) Competitors Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock GLYC vs. ITRM, PLUR, STTK, ABVC, EGRX, AKTX, BRNS, ACRV, KPTI, and TELOShould you be buying GlycoMimetics stock or one of its competitors? The main competitors of GlycoMimetics include Iterum Therapeutics (ITRM), Pluri (PLUR), Shattuck Labs (STTK), ABVC BioPharma (ABVC), Eagle Pharmaceuticals (EGRX), Akari Therapeutics (AKTX), Barinthus Biotherapeutics (BRNS), Acrivon Therapeutics (ACRV), Karyopharm Therapeutics (KPTI), and Telomir Pharmaceuticals (TELO). These companies are all part of the "pharmaceutical products" industry. GlycoMimetics vs. Its Competitors Iterum Therapeutics Pluri Shattuck Labs ABVC BioPharma Eagle Pharmaceuticals Akari Therapeutics Barinthus Biotherapeutics Acrivon Therapeutics Karyopharm Therapeutics Telomir Pharmaceuticals GlycoMimetics (NASDAQ:GLYC) and Iterum Therapeutics (NASDAQ:ITRM) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, media sentiment, dividends, earnings, risk, analyst recommendations, valuation and institutional ownership. Is GLYC or ITRM more profitable? Iterum Therapeutics' return on equity of 0.00% beat GlycoMimetics' return on equity.Company Net Margins Return on Equity Return on Assets GlycoMimeticsN/A -230.74% -177.39% Iterum Therapeutics N/A N/A -71.37% Which has better valuation & earnings, GLYC or ITRM? Iterum Therapeutics has lower revenue, but higher earnings than GlycoMimetics. Iterum Therapeutics is trading at a lower price-to-earnings ratio than GlycoMimetics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGlycoMimetics$10K0.00-$37.88M-$0.46N/AIterum TherapeuticsN/AN/A-$24.77M-$0.99-0.96 Does the media favor GLYC or ITRM? In the previous week, Iterum Therapeutics had 5 more articles in the media than GlycoMimetics. MarketBeat recorded 5 mentions for Iterum Therapeutics and 0 mentions for GlycoMimetics. Iterum Therapeutics' average media sentiment score of 0.14 beat GlycoMimetics' score of 0.00 indicating that Iterum Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment GlycoMimetics Neutral Iterum Therapeutics Neutral Do analysts rate GLYC or ITRM? Iterum Therapeutics has a consensus price target of $9.00, suggesting a potential upside of 846.37%. Given Iterum Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Iterum Therapeutics is more favorable than GlycoMimetics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score GlycoMimetics 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50Iterum Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do insiders and institutionals have more ownership in GLYC or ITRM? 75.2% of GlycoMimetics shares are held by institutional investors. Comparatively, 9.2% of Iterum Therapeutics shares are held by institutional investors. 8.7% of GlycoMimetics shares are held by insiders. Comparatively, 9.2% of Iterum Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Which has more risk and volatility, GLYC or ITRM? GlycoMimetics has a beta of 1.62, suggesting that its stock price is 62% more volatile than the S&P 500. Comparatively, Iterum Therapeutics has a beta of 2.79, suggesting that its stock price is 179% more volatile than the S&P 500. SummaryIterum Therapeutics beats GlycoMimetics on 9 of the 13 factors compared between the two stocks. Get GlycoMimetics News Delivered to You Automatically Sign up to receive the latest news and ratings for GLYC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding GLYC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GLYC vs. The Competition Export to ExcelMetricGlycoMimeticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$10.00M$839.47M$5.55B$9.05BDividend YieldN/A4.84%5.24%4.01%P/E Ratio-0.341.1527.6120.23Price / SalesN/A228.55417.23118.52Price / CashN/A23.4436.8958.10Price / BookN/A6.328.035.67Net Income-$37.88M-$27.99M$3.18B$249.21M7 Day PerformanceN/A2.11%2.93%3.28%1 Month Performance-99.22%10.13%3.75%5.55%1 Year Performance-99.42%11.60%35.20%21.09% GlycoMimetics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GLYCGlycoMimetics1.1705 of 5 starsN/AN/A-99.4%$10.00M$10K-0.3450High Trading VolumeITRMIterum Therapeutics1.9069 of 5 stars$1.00-1.5%$9.00+804.5%-15.1%$39.80MN/A-1.0110News CoveragePLURPluri3.5591 of 5 stars$4.95-2.8%$12.00+142.4%+2.1%$38.76M$330K-0.90150News CoveragePositive NewsInsider TradeSTTKShattuck Labs2.8583 of 5 stars$0.79-7.3%$7.50+847.2%-77.4%$37.93M$5.72M-0.57100Gap UpABVCABVC BioPharma0.6925 of 5 stars$2.22-14.3%N/A+315.1%$37.70M$510K-17.0830News CoveragePositive NewsHigh Trading VolumeEGRXEagle PharmaceuticalsN/A$2.90+7.4%N/A-45.5%$37.66M$257.55M0.00100Gap DownAKTXAkari Therapeutics1.5428 of 5 stars$1.17+0.9%N/A-62.9%$37.64MN/A0.009BRNSBarinthus Biotherapeutics2.8101 of 5 stars$0.93+1.5%$6.25+572.0%-31.8%$37.52M$14.97M-0.57107News CoverageGap UpACRVAcrivon Therapeutics2.6238 of 5 stars$1.19-0.8%$17.71+1,388.6%-78.9%$37.31MN/A-0.5458KPTIKaryopharm Therapeutics3.8397 of 5 stars$4.31-1.8%$43.20+902.3%-62.8%$37.24M$145.24M-0.32380TELOTelomir Pharmaceuticals2.8056 of 5 stars$1.25-18.3%$15.00+1,100.0%-68.5%$37.20MN/A-2.981High Trading Volume Related Companies and Tools Related Companies Iterum Therapeutics Alternatives Pluri Alternatives Shattuck Labs Alternatives ABVC BioPharma Alternatives Eagle Pharmaceuticals Alternatives Akari Therapeutics Alternatives Barinthus Biotherapeutics Alternatives Acrivon Therapeutics Alternatives Karyopharm Therapeutics Alternatives Telomir Pharmaceuticals Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:GLYC) was last updated on 7/5/2025 by MarketBeat.com Staff From Our PartnersBanks aren’t ready for this altcoin—are you?Our expert analysts have identified a $100 billion gap in the crypto market. Only one project is perfectly ...Crypto 101 Media | SponsoredA new rule goes live in July — and the banks are quietly cashing inA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | SponsoredTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding GlycoMimetics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share GlycoMimetics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free GLYC Stock Alerts